BioCryst hopes to raise $57.8M in stock offering to fund R&D efforts

11/18/2009 | American City Business Journals

BioCryst Pharmaceuticals plans to sell 5 million shares of stock in order to secure $57.8 million. The biotech company will use the money from the stock offering to fund clinical studies of lymphoma treatment Forodesine and BCX-4208, a gout drug, as well as support premarketing efforts for Forodesine and flu drug Peramivir.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX